Therapeutic strategies that act on the peripheral nervous system in primary headache disorders

References

• Schwedt TJ, Vargas B. Neurostimulation for treatment of migraine and cluster headache. Pain Med. 2015;16(9):1827–1834.
   PubMed Web of Science ®Google Scholar
• Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. Nat Rev Neurol. 2016;12(11):635–650.
   PubMed Web of Science ®Google Scholar
• Zagami AS. Treatment of the patient with refractory headache. Curr Pain Headache Rep. 2018;22(4):23.
   PubMed Web of Science ®Google Scholar
• May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455–464.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• Robbins MS, Lipton RB. Transcutaneous and percutaneous neurostimulation for headache disorders. Headache. 2017;57(Suppl 1):4–13.
   PubMedGoogle Scholar
• Liu Y, Dong Z, Wang R, et al. Migraine prevention using different frequencies of transcutaneous occipital nerve stimulation: a randomized controlled trial. J Pain. 2017;18(8):1006–1015.
   PubMed Web of Science ®Google Scholar
• Nguyen JP, Nizard J, Kuhn E, et al. A good preoperative response to transcutaneous electrical nerve stimulation predicts a better therapeutic effect of implanted occipital nerve stimulation in pharmacologically intractable headaches. Neurophysiol Clin. 2016;46(1):69–75.
   PubMed Web of Science ®Google Scholar
• Solomon S, Guglielmo KM. Treatment of headache by transcutaneous electrical stimulation. Headache. 1985;25(1):12–15.
   PubMed Web of Science ®Google Scholar
• Russo A, Tessitore A, Esposito F, et al. Functional changes of the perigenual part of the anterior cingulate cortex after external trigeminal neurostimulation in migraine patients. Front Neurol. 2017;8:282.
   PubMed Web of Science ®Google Scholar
• Magis D, D’Ostilio K, Thibaut A, et al. Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia. 2017;37(9):881–891.
   PubMed Web of Science ®Google Scholar
• Schoenen J, Coppola G. Efficacy and mode of action of external trigeminal neurostimulation in migraine. Expert Rev Neurother. 2018;18(7):545–555.
   PubMed Web of Science ®Google Scholar
• Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80(8):697–704.
   PubMed Web of Science ®Google Scholar
• Magis D, Sava S, d’Elia TS, et al. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the cefaly(R) device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14:95.
   PubMedGoogle Scholar
• Chou DE, Shnayderman Yugrakh M, Winegarner D, et al. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia. 2018;333102418811573.
   Google Scholar
• Penning S, Schoenen J. A survey on migraine attack treatment with the CEFALY((R)) device in regular users. Acta Neurol Belg. 2017;117(2):547–549.
   PubMed Web of Science ®Google Scholar
• Beekwilder JP, Beems T. Overview of the clinical applications of vagus nerve stimulation. J Clin Neurophysiol. 2010;27(2):130–138.
   PubMed Web of Science ®Google Scholar
• Lyubashina OA, Sokolov AY, Panteleev SS. Vagal afferent modulation of spinal trigeminal neuronal responses to dural electrical stimulation in rats. Neuroscience. 2012;222:29–37.
   PubMed Web of Science ®Google Scholar
• Gaul C, Diener HC, Silver N, et al. Non-invasive vagus nerve stimulation for prevention and acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Cephalalgia. 2016;36(6):534–546.
   PubMed Web of Science ®Google Scholar
• Barbanti P, Grazzi L, Egeo G, et al. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. J Headache Pain. 2015;16:61.
   PubMed Web of Science ®Google Scholar
• Johnson RL, Wilson CG. A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res. 2018;11:203–213.
   PubMed Web of Science ®Google Scholar
• Leone M, Cecchini AP. Central and Peripheral neural targets for neurostimulation of chronic headaches. Curr Pain Headache Rep. 2017;21(3):16.
   PubMed Web of Science ®Google Scholar
• Csati A, Tajti J, Tuka B, et al. Calcitonin gene-related peptide and its receptor components in the human sphenopalatine ganglion – interaction with the sensory system. Brain Res. 2012;1435:29–39.
   PubMed Web of Science ®Google Scholar
• Csati A, Tajti J, Kuris A, et al. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. Neuroscience. 2012;202:158–168.
   PubMed Web of Science ®Google Scholar
• Chen SP, Ay I, de Morais AL, et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain. 2016;157(4):797–805.
   PubMed Web of Science ®Google Scholar
• Ferguson AV, Samson WK. The orexin/hypocretin system: a critical regulator of neuroendocrine and autonomic function. Front Neuroendocrinol. 2003;24(3):141–150.
   PubMed Web of Science ®Google Scholar
• Holland P, Goadsby PJ. The hypothalamic orexinergic system: pain and primary headaches. Headache. 2007;47(6):951–962.
   PubMed Web of Science ®Google Scholar
• Strother LC, Srikiatkhachorn A, Supronsinchai W. Targeted orexin and hypothalamic neuropeptides for migraine. Neurotherapeutics. 2018;15(2):377–390.
   PubMed Web of Science ®Google Scholar
• Sadler RM, Purdy RA, Rahey S. Vagal nerve stimulation aborts migraine in patient with intractable epilepsy. Cephalalgia. 2002;22(6):482–484.
   PubMed Web of Science ®Google Scholar
• Yuan H, Silberstein SD. Vagus nerve and vagus nerve stimulation, a comprehensive review: part I. Headache. 2016;56(1):71–78.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study. Neurology. 2016;87(5):529–538.
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Grazzi L, de Tommaso M, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology. 2018;91(4):e364–e373.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Grosberg BM, Mauskop A, et al. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia. 2014;34(12):986–993.
   PubMed Web of Science ®Google Scholar
• Grazzi L, Egeo G, Liebler E, et al. Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study. Neurol Sci. 2017;38(Suppl 1):197–199.
   PubMed Web of Science ®Google Scholar
• Grazzi L, Egeo G, Calhoun AH, et al. Non-invasive Vagus Nerve stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. J Headache Pain. 2016;17(1):91.
   PubMedGoogle Scholar
• Kinfe TM, Pintea B, Muhammad S, et al. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. J Headache Pain. 2015;16:101.
   PubMed Web of Science ®Google Scholar
• Redgrave J, Day D, Leung H, et al. Safety and tolerability of transcutaneous Vagus Nerve stimulation in humans; a systematic review. Brain Stimul. 2018;11(6):1225–1238.
   PubMed Web of Science ®Google Scholar
• Straube A, Ellrich J, Eren O, et al. Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial. J Headache Pain. 2015;16:543.
   PubMed Web of Science ®Google Scholar
• Mercante B, Ginatempo F, Manca A, et al. Anatomo-physiologic basis for auricular stimulation. Med Acupunct. 2018;30(3):141–150.
   PubMed Web of Science ®Google Scholar
• Trentman TL, Schwedt TJ. Occipital nerve stimulation and beyond: when is invasive peripheral stimulation for headaches appropriate? Expert Rev Neurother. 2016;16(3):237–239.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Jensen RH, Antal A, et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. J Headache Pain. 2013;14:86.
   PubMed Web of Science ®Google Scholar
• Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. Lancet Neurol. 2012;11(8):708–719.
   PubMed Web of Science ®Google Scholar
• Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain. 2002;125(Pt 7):1496–1509.
   PubMed Web of Science ®Google Scholar
• Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain. 2003;126(Pt 8):1801–1813.
   PubMed Web of Science ®Google Scholar
• Ambrosini A, Schoenen J. Invasive pericranial nerve interventions. Cephalalgia. 2016;36(12):1156–1169.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Reed KL, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2015;35(4):344–358.
   PubMed Web of Science ®Google Scholar
• Slotty PJ, Bara G, Kowatz L, et al. Occipital nerve stimulation for chronic migraine: a randomized trial on subthreshold stimulation. Cephalalgia. 2015;35(1):73–78.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012;32(16):1165–1179.
   PubMed Web of Science ®Google Scholar
• Rodrigo D, Acin P, Bermejo P. Occipital nerve stimulation for refractory chronic migraine: results of a long-term prospective study. Pain Physician. 2017;20(1):E151–E159.
   PubMed Web of Science ®Google Scholar
• Miller S, Watkins L, Matharu M. Long-term follow up of intractable chronic short lasting unilateral neuralgiform headache disorders treated with occipital nerve stimulation. Cephalalgia. 2018;38(5):933–942.
   PubMed Web of Science ®Google Scholar
• Serra G, Marchioretto F. Occipital nerve stimulation for chronic migraine: a randomized trial. Pain Physician. 2012;15(3):245–253.
   PubMed Web of Science ®Google Scholar
• Hann S, Sharan A. Dual occipital and supraorbital nerve stimulation for chronic migraine: a single-center experience, review of literature, and surgical considerations. Neurosurg Focus. 2013;35(3):E9.
   PubMed Web of Science ®Google Scholar
• Clark SW, Wu C, Boorman DW, et al. Long-term pain reduction does not imply improved functional outcome in patients treated with combined supraorbital and occipital nerve stimulation for chronic migraine. Neuromodulation. 2016;19(5):507–514.
   PubMed Web of Science ®Google Scholar
• Palmisani S, Al-Kaisy A, Arcioni R, et al. A six year retrospective review of occipital nerve stimulation practice–controversies and challenges of an emerging technique for treating refractory headache syndromes. J Headache Pain. 2013;14:67.
   PubMedGoogle Scholar
• Notaro P, Buratti E, Meroni A, et al. The effects of peripheral occipital nerve stimulation for the treatment of patients suffering from chronic migraine: a single center experience. Pain Physician. 2014;17(3):E369–374.
   PubMed Web of Science ®Google Scholar
• Lendvai IS, Maier A, Scheele D, et al. Spotlight on cervical vagus nerve stimulation for the treatment of primary headache disorders: a review. J Pain Res. 2018;11:1613–1625.
   PubMed Web of Science ®Google Scholar
• Pintea B, Hampel K, Bostrom J, et al. Extended long-term effects of cervical vagal nerve stimulation on headache intensity/frequency and affective/cognitive headache perception in drug resistant complex-partial seizure patients. Neuromodulation. 2017;20(4):375–382.
   PubMed Web of Science ®Google Scholar
• Gul HL, Ozon AO, Karadas O, et al. The efficacy of greater occipital nerve blockade in chronic migraine: A placebo-controlled study. Acta Neurol Scand. 2017;136(2):138–144.
   PubMed Web of Science ®Google Scholar
• Cuadrado ML, Aledo-Serrano A, Navarro P, et al. Short-term effects of greater occipital nerve blocks in chronic migraine: A double-blind, randomised, placebo-controlled clinical trial. Cephalalgia. 2017;37(9):864–872.
   PubMed Web of Science ®Google Scholar
• Palamar D, Uluduz D, Saip S, et al. Ultrasound-guided greater occipital nerve block: an efficient technique in chronic refractory migraine without aura? Pain Physician. 2015;18(2):153–162.
   PubMed Web of Science ®Google Scholar
• Inan LE, Inan N, Karadas O, et al. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand. 2015;132(4):270–277.
   PubMed Web of Science ®Google Scholar
• Cuadrado ML, Aledo-Serrano A, Lopez-Ruiz P, et al. Greater occipital nerve block for the acute treatment of prolonged or persistent migraine aura. Cephalalgia. 2017;37(8):812–818.
   PubMed Web of Science ®Google Scholar
• Cohen SP, Peterlin BL, Fulton L, et al. Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness. Pain. 2015;156(12):2585–2594.
   PubMed Web of Science ®Google Scholar
• Dilli E, Halker R, Vargas B, et al. Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study. Cephalalgia. 2015;35(11):959–968.
   PubMed Web of Science ®Google Scholar
• Kashipazha D, Nakhostin-Mortazavi A, Mohammadianinejad SE, et al. Preventive effect of greater occipital nerve block on severity and frequency of migraine headache. Global J Health Sci. 2014;6(6):209–213.
   PubMedGoogle Scholar
• Korucu O, Dagar S, Corbacioglu SK, et al. The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments. Acta Neurol Scand. 2018;138(3):212–218.
   PubMed Web of Science ®Google Scholar
• Inan N, Inan LE, Coskun O, et al. Effectiveness of greater occipital nerve blocks in migraine prophylaxis. Noro Psikiyatri Ars. 2016;53(1):45–48.
   PubMedGoogle Scholar
• Unal-Artik HA, Inan LE, Atac-Ucar C, et al. Do bilateral and unilateral greater occipital nerve block effectiveness differ in chronic migraine patients? Neurol Sci. 2017;38(6):949–954.
   PubMed Web of Science ®Google Scholar
• Allen SM, Mookadam F, Cha SS, et al. Greater occipital nerve block for acute treatment of migraine headache: a large retrospective cohort study. J Am Board Fam Med. 2018;31(2):211–218.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang X, Lin Y, et al. The efficacy of greater occipital nerve block for the treatment of migraine: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2018;165:129–133.
   PubMed Web of Science ®Google Scholar
• Tang Y, Kang J, Zhang Y, et al. Influence of greater occipital nerve block on pain severity in migraine patients: A systematic review and meta-analysis. Am J Emerg Med. 2017;35(11):1750–1754.
   PubMed Web of Science ®Google Scholar
• Vukovic Cvetkovic V, Jensen RH. Neurostimulation for the treatment of chronic migraine and cluster headache. Acta Neurol Scand. 2019;139(1):4-17.
   Web of Science ®Google Scholar
• Khan S, Schoenen J, Ashina M. Sphenopalatine ganglion neuromodulation in migraine: what is the rationale? Cephalalgia. 2014;34(5):382–391.
   PubMed Web of Science ®Google Scholar
• Cady R, Saper J, Dexter K, et al. A double-blind, placebo-controlled study of repetitive transnasal sphenopalatine ganglion blockade with tx360((R)) as acute treatment for chronic migraine. Headache. 2015;55(1):101–116.
   PubMed Web of Science ®Google Scholar
• Cady RK, Saper J, Dexter K, et al. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine. Headache. 2015;55(4):529–542.
   PubMed Web of Science ®Google Scholar
• Bratbak DF, Nordgard S, Stovner LJ, et al. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalalgia. 2017;37(4):356–364.
   PubMed Web of Science ®Google Scholar
• Binfalah M, Alghawi E, Shosha E, et al. Sphenopalatine ganglion block for the treatment of acute migraine headache. Pain Res Treat. 2018;2516953:2018.
   Google Scholar
• Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002;27(11):552–558.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Onabotulinumtoxin A (BOTOX(R)): a review of its use in the prophylaxis of headaches in adults with chronic migraine. Drugs. 2012;72(6):825–845.
   PubMed Web of Science ®Google Scholar
• De Boulle K, Fagien S, Sommer B, et al. Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction. Clin Interv Aging. 2010;5:101–118.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollon E, Ramon C, Martinez-Camblor P, et al. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;156(5):820–824.
   PubMed Web of Science ®Google Scholar
• Cady R, Turner I, Dexter K, et al. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine. Headache. 2014;54(2):269–277.
   PubMed Web of Science ®Google Scholar
• Hollanda L, Monteiro L, Melo A. Botulinum toxin type a for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial. Neurol Int. 2014;6(4):5133.
   PubMedGoogle Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–814.
   PubMed Web of Science ®Google Scholar
• Szok D, Csati A, Vecsei L, et al. Treatment of chronic migraine with onabotulinumtoxina: mode of action, efficacy and safety. Toxins (Basel). 2015;7(7):2659–2673.
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Tuka B, et al. Botulinum neurotoxin–a therapy in migraine. Ideggyogy Szemle. 2012;65(3–4):77–82.
   PubMedGoogle Scholar
• Vecsei L, Majlath Z, Szok D, et al. Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf. 2015;14(5):667–681.
   PubMed Web of Science ®Google Scholar
• Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6:CD011616.
   PubMedGoogle Scholar
• Tassorelli C, Tedeschi G, Sarchielli P, et al. Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Rev Neurother. 2018;18(2):167–176.
   PubMed Web of Science ®Google Scholar
• Negro A, Curto M, Lionetto L, et al. Chronic migraine treatment: from onabotulinumtoxin A onwards. Expert Rev Neurother. 2016;16(10):1217–1227.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–187.
   PubMed Web of Science ®Google Scholar
• Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350.
   PubMed Web of Science ®Google Scholar
• Vecsei L, Lukacs M, Tajti J, et al. The therapeutic impact of new migraine discoveries. Curr Med Chem. 2018 May 29. doi: 10.2174/0929867325666180530114534.
   Google Scholar
• Vecsei L, Tuka B, Tajti J. Role of PACAP in migraine headaches. Brain. 2014;137(Pt 3):650–651.
   PubMedGoogle Scholar
• Tajti J, Szok D, Majlath Z, et al. Migraine and neuropeptides. Neuropeptides. 2015;52:19–30.
   PubMed Web of Science ®Google Scholar
• Tajti J, Pardutz A, Vamos E, et al. Migraine is a neuronal disease. J Neural Transm. 2011;118(4):511–524.
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Pardutz A, et al. Where does a migraine attack originate? In the brainstem. J Neural Transm. 2012;119(5):557–568.
   PubMed Web of Science ®Google Scholar
• Tajti J, Uddman R, Moller S, et al. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999;76(2–3):176–183.
   PubMedGoogle Scholar
• Eftekhari S, Salvatore CA, Johansson S, et al. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. relation to the blood-brain barrier. Brain Res. 2015;1600:93–109.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Villalon CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther. 2012;136(3):319–333.
   PubMed Web of Science ®Google Scholar
• Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365–391.
   PubMed Web of Science ®Google Scholar
• Edvinsson L. Headache advances in 2017: a new horizon in migraine therapy. Lancet Neurol. 2018;17(1):5–6.
   PubMed Web of Science ®Google Scholar
• Vecsei L, Szok D, Csati A, et al. CGRP antagonists and antibodies for the treatment of migraine. Expert Opin Investig Drugs. 2015;24(1):31–41.
   PubMed Web of Science ®Google Scholar
• Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39(3):445–458.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol. 2002;1(4):251–257.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Mechtler LL, Kudrow DB, et al. Non-invasive vagus nerve stimulation for the acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache. 2016;56(8):1317–1332.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, de Coo IF, Silver N, et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia. 2018;38(5):959–969.
   PubMed Web of Science ®Google Scholar
• Morris J, Straube A, Diener HC, et al. Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache. J Headache Pain. 2016;17:43.
   PubMed Web of Science ®Google Scholar
• Mwamburi M, Liebler EJ, Tenaglia AT. Cost-effectiveness of gammaCore (non-invasive vagus nerve stimulation) for acute treatment of episodic cluster headache. Am J Manag Care. 2017;23(16 Suppl):S300–S306.
   PubMedGoogle Scholar
• Magis D, Bruno MA, Fumal A, et al. Central modulation in cluster headache patients treated with occipital nerve stimulation: an FDG-PET study. BMC Neurol. 2011;11:25.
   PubMed Web of Science ®Google Scholar
• Matharu MS, Bartsch T, Ward N, et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain. 2004;127(Pt 1):220–230.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, May A. PET demonstration of hypothalamic activation in cluster headache. Neurology. 1999;52(7):1522.
   PubMed Web of Science ®Google Scholar
• Wilbrink LA, Teernstra OP, Haan J, et al. Occipital nerve stimulation in medically intractable, chronic cluster headache. The ICON study: rationale and protocol of a randomised trial. Cephalalgia. 2013;33(15):1238–1247.
   PubMed Web of Science ®Google Scholar
• Brewer AC, Trentman TL, Ivancic MG, et al. Long-term outcome in occipital nerve stimulation patients with medically intractable primary headache disorders. Neuromodulation. 2013;16(6):557–562. discussion 563–554
   PubMed Web of Science ®Google Scholar
• Leone M, Proietti Cecchini A, Messina G, et al. Long-term occipital nerve stimulation for drug-resistant chronic cluster headache. Cephalalgia. 2017;37(8):756–763.
   PubMed Web of Science ®Google Scholar
• Mueller O, Diener HC, Dammann P, et al. Occipital nerve stimulation for intractable chronic cluster headache or migraine: a critical analysis of direct treatment costs and complications. Cephalalgia. 2013;33(16):1283–1291.
   PubMed Web of Science ®Google Scholar
• Lainez MJ, Guillamon E. Cluster headache and other TACs: pathophysiology and neurostimulation options. Headache. 2017;57(2):327–335.
   PubMed Web of Science ®Google Scholar
• Fontaine D, Blond S, Lucas C, et al. Occipital nerve stimulation improves the quality of life in medically-intractable chronic cluster headache: results of an observational prospective study. Cephalalgia. 2017;37(12):1173–1179.
   PubMed Web of Science ®Google Scholar
• Leone M, Giustiniani A, Cecchini AP. Cluster headache: present and future therapy. Neurol Sci. 2017;38(Suppl 1):45–50.
   PubMedGoogle Scholar
• Cadalso RT Jr., Daugherty J, Holmes C, et al. Efficacy of electrical stimulation of the occipital nerve in intractable primary headache disorders: a systematic review with meta-analyses. J Oral Facial Pain Headache. 2018;32(1):40–52.
   PubMed Web of Science ®Google Scholar
• Barloese MC, Jurgens TP, May A, et al. Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months. J Headache Pain. 2016;17(1):67.
   PubMedGoogle Scholar
• Ho KWD, Przkora R, Kumar S. Sphenopalatine ganglion: block, radiofrequency ablation and neurostimulation - a systematic review. J Headache Pain. 2017;18(1):118.
   PubMedGoogle Scholar
• Robbins MS, Robertson CE, Kaplan E, et al. The sphenopalatine ganglion: anatomy, pathophysiology, and therapeutic targeting in headache. Headache. 2016;56(2):240–258.
   PubMed Web of Science ®Google Scholar
• Schoenen J, Jensen RH, Lanteri-Minet M, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. pathway CH-1: a randomized, sham-controlled study. Cephalalgia. 2013;33(10):816–830.
   PubMed Web of Science ®Google Scholar
• Jurgens TP, Barloese M, May A, et al. Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. Cephalalgia. 2017;37(5):423–434.
   PubMed Web of Science ®Google Scholar
• Barloese M, Petersen A, Stude P, et al. Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry. J Headache Pain. 2018;19(1):6.
   PubMedGoogle Scholar
• Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain. 2005;118(1–2):92–96.
   PubMed Web of Science ®Google Scholar
• Rozen TD. High-volume Anesthetic Suboccipital nerve blocks for treatment refractory chronic cluster headache with long-term efficacy data: an observational case series study. Headache. 2019;59(1):56-62.
   Web of Science ®Google Scholar
• Lambru G, Abu Bakar N, Stahlhut L, et al. Greater occipital nerve blocks in chronic cluster headache: a prospective open-label study. Eur J Neurol. 2014;21(2):338–343.
   PubMed Web of Science ®Google Scholar
• Wei J, Robbins MS. Greater occipital nerve injection versus oral steroids for short term prophylaxis of cluster headache: a retrospective comparative study. Headache. 2018;58(6):852–858.
   PubMed Web of Science ®Google Scholar
• Gantenbein AR, Lutz NJ, Riederer F, et al. Efficacy and safety of 121 injections of the greater occipital nerve in episodic and chronic cluster headache. Cephalalgia. 2012;32(8):630–634.
   PubMed Web of Science ®Google Scholar
• Gaul C, Roguski J, Dresler T, et al. Efficacy and safety of a single occipital nerve blockade in episodic and chronic cluster headache: A prospective observational study. Cephalalgia. 2017;37(9):873–880.
   PubMed Web of Science ®Google Scholar
• Leroux E, Valade D, Taifas I, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(10):891–897.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Giamberardino MA, Mitsikostas DD. Greater occipital nerve as target for refractory chronic headaches: from corticosteroid block to invasive neurostimulation and back. Expert Rev Neurother. 2016;16(8):865–866.
   PubMed Web of Science ®Google Scholar
• Fang L, Jingjing L, Ying S, et al. Computerized tomography-guided sphenopalatine ganglion pulsed radiofrequency treatment in 16 patients with refractory cluster headaches: twelve- to 30-month follow-up evaluations. Cephalalgia. 2016;36(2):106–112.
   PubMed Web of Science ®Google Scholar
• Bendersky DC, Hem SM, Yampolsky CG. Unsuccessful pulsed radiofrequency of the sphenopalatine ganglion in patients with chronic cluster headache and subsequent successful thermocoagulation. Pain Pract. 2015;15(5):E40–45.
   PubMed Web of Science ®Google Scholar
• Bratbak DF, Nordgard S, Stovner LJ, et al. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache. Cephalalgia. 2016;36(6):503–509.
   PubMed Web of Science ®Google Scholar
• Kastler A, Cadel G, Comte A, et al. Alcohol percutaneous neurolysis of the sphenopalatine ganglion in the management of refractory cranio-facial pain. Neuroradiology. 2014;56(7):589–596.
   PubMed Web of Science ®Google Scholar
• Sostak P, Krause P, Forderreuther S, et al. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain. 2007;8(4):236–241.
   PubMed Web of Science ®Google Scholar
• Lampl C, Rudolph M, Brautigam E. OnabotulinumtoxinA in the treatment of refractory chronic cluster headache. J Headache Pain. 2018;19(1):45.
   PubMedGoogle Scholar
• Lambru G, Matharu MS. SUNCT and SUNA: medical and surgical treatments. Neurol Sci. 2013;34(Suppl 1):S75–81.
   PubMed Web of Science ®Google Scholar
• Miller S, Watkins L, Matharu MS. Treatment of intractable hemicrania continua by occipital nerve stimulation. J Neurol Neurosurg Psychiatry. 2017;88(9):805–806.
   PubMed Web of Science ®Google Scholar
• Trimboli M, Al-Kaisy A, Andreou AP, et al. Non-invasive vagus nerve stimulation for the management of refractory primary chronic headaches: A real-world experience. Cephalalgia. 2018;38(7):1276–1285.
   PubMed Web of Science ®Google Scholar
• Tso AR, Marin J, Goadsby PJ. Noninvasive vagus nerve stimulation for treatment of indomethacin-sensitive headaches. JAMA Neurol. 2017;74(10):1266–1267.
   PubMed Web of Science ®Google Scholar
• Arca KN, Halker Singh RB. SUNCT and SUNA: an update and review. Curr Pain Headache Rep. 2018;22(8):56.
   PubMed Web of Science ®Google Scholar
• Lambru G, Shanahan P, Watkins L, et al. Occipital nerve stimulation in the treatment of medically intractable SUNCT and SUNA. Pain Physician. 2014;17(1):29–41.
   PubMed Web of Science ®Google Scholar
• Baraldi C, Pellesi L, Guerzoni S, et al. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. J Headache Pain. 2017;18(1):71.
   PubMedGoogle Scholar
• Guerrero AL, Herrero-Velazquez S, Penas ML, et al. Peripheral nerve blocks: a therapeutic alternative for hemicrania continua. Cephalalgia. 2012;32(6):505–508.
   PubMed Web of Science ®Google Scholar
• Androulakis XM, Krebs KA, Ashkenazi A. Hemicrania continua may respond to repetitive sphenopalatine ganglion block: A case report. Headache. 2016;56(3):573–579.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs. 2012;26(5):375–382.
   PubMed Web of Science ®Google Scholar
• Miller S, Matharu MS. Migraine is underdiagnosed and undertreated. Practitioner. 2014;258(1774):19–24, 12–13.
   PubMedGoogle Scholar
• Tajti J, Tuka B, Botz B, et al. Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine. CNS Neurol Disord Drug Targets. 2015;14(4):540–553.
   PubMed Web of Science ®Google Scholar
• Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132(Pt 1):16–25.
   PubMedGoogle Scholar
• Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 2013;33(13):1085–1095.
   PubMed Web of Science ®Google Scholar
• Tuka B, Szabo N, Toth E, et al. Release of PACAP-38 in episodic cluster headache patients - an exploratory study. J Headache Pain. 2016;17(1):69.
   PubMedGoogle Scholar
• Rubio-Beltran E, Correnti E, Deen M, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018;19(1):64.
   PubMedGoogle Scholar
• Guo S, Vecsei L, Ashina M. The L-kynurenine signalling pathway in trigeminal pain processing: a potential therapeutic target in migraine? Cephalalgia. 2011;31(9):1029–1038.
   PubMed Web of Science ®Google Scholar
• Curto M, Lionetto L, Fazio F, et al. Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important. Intern Emerg Med. 2015;10(4):413–421.
   PubMed Web of Science ®Google Scholar
• Vecsei L, Szalardy L, Fulop F, et al. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov. 2013;12(1):64–82.
   PubMed Web of Science ®Google Scholar
• Tajti J, Majlath Z, Szok D, et al. Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders: preclinical studies and pharmaceutical design. Curr Pharm Des. 2015;21(17):2250–2258.
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Nagy-Grocz G, et al. Kynurenines and PACAP in migraine: medicinal chemistry and pathogenetic aspects. Curr Med Chem. 2017;24(13):1332–1349.
   PubMed Web of Science ®Google Scholar
• Kortesi T, Tuka B, Tajti J, et al. Kynurenic acid inhibits the electrical stimulation induced elevated pituitary adenylate cyclase-activating polypeptide expression in the TNC. Front Neurol. 2017;8:745.
   PubMed Web of Science ®Google Scholar
• Curto M, Lionetto L, Negro A, et al. Altered kynurenine pathway metabolites in serum of chronic migraine patients. J Headache Pain. 2015;17:47.
   PubMed Web of Science ®Google Scholar